THNR
Amplify Weight Loss Drug & Treatment ETF
Price Chart
Latest Quote
$24.57
-0.05 (-0.21%)
Current Price
| Previous Close | $24.62 |
| Open | $24.57 |
| Day High | $24.62 |
| Day Low | $24.62 |
| Volume | 603 |
Fund Information
| Quarterly Dividend / Yield | N/A / 1.64% |
| Net Assets | $5.78M |
| Expense Ratio | 0.59% |
| Category | Health |
| Fund Family | Amplify ETFs |
| Net Asset Value | $24.59 |
| Premium/Discount | -0.07% |
| Quarterly Dividend Yield | 1.64% |
| P/E Ratio | 20.16 |
| Exchange | PCX |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $24.57 |
| SMA50 | $25.63 |
| SMA200 | $25.32 |
| RSI | 55.29 |
| ATR | 0.3570 |
| Rel Volume | 0.71 |
Performance History
| Week | -1.42% |
| Month | -2.21% |
| Quarter | -5.00% |
| 6 Months | +4.17% |
| YTD | -3.35% |
| Year | +7.85% |
| 10 Years | -0.75% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-28 | $24.57 | 603 |
| 2026-10-27 | $24.62 | 400 |
| 2026-10-26 | $24.66 | 1,400 |
| 2026-10-23 | $24.70 | 400 |
| 2026-10-22 | $24.95 | 2,700 |
| 2026-10-21 | $24.92 | 400 |
| 2026-10-20 | $25.06 | 100 |
| 2026-10-19 | $24.40 | 600 |
| 2026-10-16 | $24.50 | 700 |
| 2026-10-15 | $24.74 | 200 |
| 2026-10-14 | $24.17 | 800 |
| 2026-10-13 | $24.03 | 300 |
| 2026-10-12 | $24.43 | 100 |
| 2026-10-09 | $24.52 | 1,600 |
| 2026-10-08 | $24.25 | 1,000 |
| 2026-10-07 | $24.70 | 800 |
| 2026-10-06 | $24.49 | 1,000 |
| 2026-10-05 | $24.47 | 1,200 |
| 2026-10-02 | $24.56 | 2,100 |
| 2026-10-01 | $24.69 | 600 |
| 2026-09-30 | $25.15 | 500 |
| 2026-09-29 | $25.12 | 100 |
| 2026-09-28 | $25.33 | 100 |
About Amplify Weight Loss Drug & Treatment ETF
The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is non-diversified.
đ° Latest News
No news articles available at the moment. Check back later for updates on THNR.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.